Biocon Limited — Q2 FY25
Biocon's Q2 FY25 consolidated revenue from operations grew 8% YoY to ₹3,590 crore, driven by biosimilars (up 19% like-for-like) but offset by generics decline (-8%) and flat Syn...
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
63%Questions answered3Evaded / deflected12Questions auditedContradictedNumbers vs filing
Answered
High priority
Revenue breakup of Biocon Biologics by region
Asked by Harith Ahamed, Spark Capital
Provided specific regional revenue split percentages.
Read the exchange
Question
Will you be able to give an indication of the breakup of these revenues between U.S., Europe, and other markets?
Kedar Upadhye, CFO, Biocon Biologics
about 40, 40, 41% of the revenues are contributed by North America, about 30% by Europe, and balance 30% by emerging markets.
Answered
Medium priority
R&D spend at Biocon Biologics for the quarter
Asked by Harith Ahamed, Spark Capital
Provided specific R&D spend in USD and INR.
Read the exchange
Question
if you can provide the R&D spends at Biocon Biologics for the quarter
Kedar Upadhye, CFO, Biocon Biologics
It's about $17 million, Harith. That's about a little higher than INR 140 crore for the quarter in Biocon Biologics.
Partial answer
High priority
Net debt increase despite Eris proceeds and high CapEx
Asked by Harith Ahamed, Spark Capital
Explained CapEx and net debt but did not fully reconcile the cash flow gap.
no specific free cash flow explanationdeferred to CapEx investments
Read the exchange
Question
despite that, there is an increase in net debt at a consolidated level of around INR 400 crores... why such a high negative free cash flow during the H1?
Kedar Upadhye, CFO, Biocon Biologics and Siddharth Mittal, MD & CEO, Biocon Limited
the biologics net debt has improved... CapEx stays in the zone of about ₹90-₹100 million for this year... At the group level, net debt was ₹1.35 billion, which has gone up to $1.4 billion.
Evasive
High priority
Does VAI for Bangalore facility pave way for Bevacizumab approval?
Asked by Surya Narayan Patra, PhillipCapital
Did not confirm whether VAI helps Bevacizumab; redirected to insulin inspection.
clarified VAI was for insulin, not Bevacizumabno direct answer on Bevacizumab timeline
Read the exchange
Question
is it fair to believe that this paves the way for the approval for Bevacizumab, which has been pending since some time?
Shreehas Tambe, MD & CEO, Biocon Biologics
The inspection that occurred in February... was for the drug substance recombinant human insulin... The other two inspections were at different locations... Bevacizumab... inspection outcome is awaited.
Answered
High priority
Key catalysts for biosimilar business over 3 years
Asked by Surya Narayan Patra, PhillipCapital
Listed specific products and timelines for biosimilar pipeline.
Read the exchange
Question
what are the key catalysts for your biosimilar business that you do believe?
Shreehas Tambe, MD & CEO, Biocon Biologics
five product launches coming up in the near to midterm... Aspart, Bevacizumab, Stelara, Denosumab, Aflibercept.
Partial answer
Medium priority
Finance cost for newly added debt and Bevacizumab Europe market size
Asked by Surya Narayan Patra, PhillipCapital
Provided finance cost details but deferred the market size question.
deferred Bevacizumab market size to offline
Read the exchange
Question
what is the kind of finance cost for the newly added debt? ... regards to Bevacizumab in Europe, what is the target market size?
Kedar Upadhye, CFO, Biocon Biologics and Shreehas Tambe, MD & CEO, Biocon Biologics
the coupon is about 6.67%... For the balance $300 million, it's linked to SOFR... spread of about 175 basis points... We'll get back to you... on the market opportunity on Europe specifically.
Partial answer
High priority
BBL margin improvement and full-year core margin outlook
Asked by Neha Manpuria, Bank of America
Provided current margin range but declined to give full-year guidance.
no specific full-year margin guidance
Read the exchange
Question
is it fair to assume that a lot of this market share expansion hasn't come at the cost of lower pricing? ... how we should be thinking about full-year core margins?
Kedar Upadhye, CFO, Biocon Biologics
EBITDA margins between 22%-25%... growth has not come at the cost of pricing... no specific guidance that we want to give at this point of time.
Evasive
High priority
Impact of Amgen's patent litigation on Aflibercept opportunity
Asked by Neha Manpuria, Bank of America
Acknowledged question but gave no concrete assessment of impact.
refused to speculate on competitor actionsno specific impact analysis
Read the exchange
Question
how does this impact the market opportunity for us when depending, obviously, on our patent litigation outcome?
Shreehas Tambe, MD & CEO, Biocon Biologics
we wouldn't want to speculate what a competitor would do... It's a very attractive, interesting opportunity... We continue to remain very excited about it.
Declined
Medium priority
Timeline for Aflibercept launch
Asked by Neha Manpuria, Bank of America
Explicitly stated no timeline available.
no timeline given
Read the exchange
Question
any timeline on the, I mean, guidance on timeline of the launch?
Shreehas Tambe, MD & CEO, Biocon Biologics
we do not have an indication of the timeline at this point in time, Neha.
Answered
High priority
Humira biosimilar market share and pricing trends
Asked by Damayanti Kerai, HSBC
Provided specific outlook on market opening and payer engagement.
Read the exchange
Question
how the market is evolving... for a player like Biocon, what are the expectations there in terms of market share gain?
Matthew Erick, CCO, Biocon Biologics
as you go into 1/1/2025... you're going to start to see the market open up... we are seeing payers reaching out directly to us.
Answered
Medium priority
Working capital improvement timeline for Biocon Biologics
Asked by Damayanti Kerai, HSBC
Provided specific inventory reduction target and receivable days.
Read the exchange
Question
when we can see some improvement coming in there?
Kedar Upadhye, CFO, Biocon Biologics
target is to reduce inventory by about $100 million... we are doing good on that front... receivable days are tracking at roughly 80.
Answered
High priority
Update on liraglutide DMF and ANDA with US FDA
Asked by Palak Shah, PL Capital Markets
Provided specific status and expected approval timeline.
Read the exchange
Question
I just wanted to check for an update for liraglutide DMF filed with U.S. FDA.
Shreehas Tambe, MD & CEO, Biocon Biologics
the DMF was accepted by the FDA... ANDA... is under review... we expect the approval sometime in the next calendar year.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Biocon Biologics Q2 revenue ~INR 2,200 cr | ₹2,200 cr | ₹3,590 cr | Understated vs filing |
| Biocon Biologics H1 revenue ~INR 4,300 cr | ₹4,300 cr | ₹3,590 cr | Overstated vs filing |
| BBL EBITDA margin trending 22%-25% | 22% | 19% | Overstated vs filing |
| Core EBITDA margin 32% for BBL | 32% | 19% | Overstated vs filing |
| Adjusted EBITDA margin 25% for BBL (excluding FX) | 25% | 19% | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.